NASDAQ : RNTX
Rein Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.67 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 57.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 57.80M |
| Enterprise Value | 17.15M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 86.27M |
| Shares Outstanding | 86.27M |
| Shares Change (YoY) | +283.20% |
| Shares Change (QoQ) | +205.88% |
| Owned by Insiders (%) | 6.02% |
| Owned by Institutions (%) | 36.37% |
| Float | 66.11M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.27 |
| Quick Ratio | 4.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -96.42% |
| Return on Assets (ROA) | -21.02% |
| Return on Invested Capital (ROIC) | -25.14% |
| Return on Capital Employed (ROCE) | -36.89% |
| Weighted Average Cost of Capital (WACC) | 11.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.98M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -712,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -56.77% |
| 50-Day Moving Average | 0.75 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 47.24 |
| Average Volume (20 Days) | 415,651 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 590,758 |
| Short Previous Month | 651,179 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 0.89% |
| Short Ratio (days to cover) | 1.39 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.76M |
| Pretax Income | -50.47M |
| Net Income | -49.76M |
| EBITDA | -20.76M |
| EBIT | -20.76M |
| Earnings Per Share (EPS) | -$0.58 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 40.65M |
| Total Debt | n/a |
| Net Cash | 40.65M |
| Net Cash Per Share | $0.47 |
| Equity (Book Value) | 55.20M |
| Book Value Per Share | 0.12 |
| Working Capital | 31.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -18.83M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 500 |
| Net Borrowing | -1.08M |
| Free Cash Flow | -18.83M |
| FCF Per Share | -$0.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -283.20% |
| Shareholder Yield | -283.20% |
| Earnings Yield | -86.60% |
| FCF Yield | -32.58% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.00 |
| Price Target Difference | 795.52% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 11, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |